Summa Equity acquires shares in HyTest

Summa Equity, a leading Nordic private equity investor, has acquired majority shareholding of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. HyTest was founded in 1994 by a group of Russian scientists who are still members of senior management. The company is based in Turku, Finland, with a key subsidiary company in Moscow, Russia. HyTest’s customer base includes a large number of companies that supply IVD equipment, including many of the global leaders in the IVD market. The company is active across the globe, including US, Asia and Europe.

Summa Equity was advised by Mannheimer Swartling on Russian law and Avance Attorneys Ltd on Finnish law.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.